Search - tctmd.com

Displaying 341 - 360 of 393

Sort: Relevancy | Date

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Caitlin E. Cox

June 30, 2016

News Daily News

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Yael L. Maxwell

June 29, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Yael L. Maxwell

May 13, 2016

News Daily News

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

Michael O'Riordan

March 25, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Daily News

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Todd Neale

January 18, 2016

News Industry News

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

January 03, 2016

News Daily News

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

L.A. McKeown

December 09, 2015

News Industry News

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

November 17, 2015

News Industry News

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

September 18, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Conference News ESC 2015

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Yael L. Maxwell

August 31, 2015

News Conference News ESC 2015

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

L.A. McKeown

August 31, 2015

News Industry News

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

August 31, 2015

News Conference News ESC 2015

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

Yael L. Maxwell

August 30, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Daily News

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Todd Neale

August 17, 2015

Advertisement

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Deadly Deceleration? Annual Declines in US Cardiovascular Death Rate Start to Slow

Don’t Dismiss Diabetes: Long-Term Mortality After Acute MI Linked With the Disease in Large Population Study

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Guidelines Notwithstanding, More Diabetics with Multivessel CAD Receive PCI Than CABG

Evidence Mounts Showing No Increased Risk of Heart Failure With Incretin-Based Antidiabetic Drugs

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Refreshed Dietary Guidelines Shift Focus to Healthy Eating Patterns

Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments

AHA Scientific Statement Highlights Sex Disparities in CV Risk Among Diabetic Patients

New Publication Featuring GlycoMark® Test Highlights Association of Hyperglycemic Excursions With Cardiovascular Outcomes And Mortality

Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics

Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients

Bayer Expands Finerenone Clinical Development Program with Three Phase III Studies for Finerenone in Patients with Diabetic Kidney Disease and Patients with Chronic Heart Failure

FREEDOM Substudy: CABG, PCI Outcomes Affected by Baseline BP

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

肌钙蛋白 T 水平高预示着 2 型糖尿病及稳定型心脏疾病患者结局不佳

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content